Serum and urine samples have been collected for measurement of angiogenic peptides. Forty eight patients have been enrolled. Twenty eight sufferers had glioblastomas, and 20 had anaplastic gliomas. The median age was 53 years, plus the median KPS was 70. Thirty two percent of sufferers had undergone one previ ous chemotherapy treatment, 34% had two, and 34% had 3 or more past chemotherapies. The therapy was fairly very well tolerated in this heavily pretreated population. No treatment method related deaths occurred. Fatigue was standard but generally mild. Two percent of individuals had a partial response, 9% had a minor response, 59% had steady condition, and 30% progressed at their very first scan. For GBM individuals, the median progression zero cost survival time was 11 weeks, the six month PFS price was 9%, along with the median total survival time was 21 weeks. For AG sufferers, the median PFS time was 14 weeks, the 6 month PFS price was 26%, and the median OS time was 41.
5 weeks. When evaluating reply ers with non responders, there was a substantial difference in OS with median point estimates for responders and non responders of 33 and 20 weeks, respectively, selleck chemicals PFS was also signifi cantly distinct with 6 month PFS estimates of 21% vs. 0% during the responder selelck kinase inhibitor as well as non responder groups, respectively. Some of the sufferers had ample serial serum or urine specimens for angiogenic peptide examination. In this limited set, serum and urine angiogenic peptides did not correlate with response or survival. This 4 drug, oral antiangiogenic chemotherapy routine was very well tolerated. Angiogenic peptide amounts didn’t correlate with survival or response. Even though there were some responders, the routine did not considerably increase OS within this heavily pretreated group of patients who had been in general not eligible for con ventional protocols.
Even further research employing antiangiogenic chemotherapy mixed with a lot more potent antiangiogenic agents in sufferers with less innovative disease may well be warranted.

TA 28. A PHASE II STUDY OF RADIATION WITH CONCOMITANT AND THEN SEQUENTIAL TEMOZOLOMIDE IN Individuals WITH NEWLY DIAGNOSED SUPRATENTORIAL HIGH GRADE MALIGNANT GLIOMA WHO HAVE UNDERGONE SURGERY WITH CARMUSTINE WAFER INSERTION R. V. La Rocca, J. Hodes, W. G. Villanueva, T. W. Vitaz, D. J. Morassutti, M. J. Doyle, S. Glisson, A.